Subtype
Neuroendocrine Carcinoma
CI-CAN-00001275NECExplore in graph →
515 active trials12 approved drugs28 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001275NECExplore in graph →
Clinical trials
1,533 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (213)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07381543 | Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone | not yet recruiting | Phase 2 | 76 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07383454 | Lung Cancer Screening in Population Who Had Never Smoked | not yet recruiting | N/A | 2,500 | Chung Shan Medical UniversityOTHER | 0 | Feb 3, 2026 | clinicaltrials |
| NCT07376499 | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction | not yet recruiting | Phase 2 | 31 | China Medical University, ChinaOTHER | 0 | Jan 29, 2026 | clinicaltrials |
| NCT07357532 | Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD | not yet recruiting | Phase 2 | 44 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07337447 | Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)(REWENEC 01) | not yet recruiting | Phase 2 | 122 | Hospices Civils de LyonOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07308379 | Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer | not yet recruiting | — | 1,200 | Fudan UniversityOTHER | 0 | Dec 29, 2025 | clinicaltrials |
| NCT07289048 | A Prospective, Single-Arm, Exploratory Study of IBI363 in ES-SCLC Patients After Immunotherapy Progression | not yet recruiting | Phase 2 | 35 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Dec 17, 2025 | clinicaltrials |
| NCT07252661 | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 40 | AccSalus Biosciences, Inc.INDUSTRY | 0 | Nov 28, 2025 | clinicaltrials |
| NCT07206563 | Penfluridol for Relapsed/Refractory Small Cell Cancers | not yet recruiting | Phase 1 / Phase 2 | 33 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT07200154 | Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC | not yet recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07173244 | A Real-world Study of Adebrelimab-based Combination Regimens in the Treatment of Advanced Solid Tumors | not yet recruiting | — | 300 | Tianjin First Central HospitalOTHER | 0 | Sep 15, 2025 | clinicaltrials |
| NCT07173946 | Prospective Observational Study on ES-SCLC | not yet recruiting | — | 96 | Peking Union Medical College HospitalOTHER | 0 | Sep 15, 2025 | clinicaltrials |
| NCT07156019 | Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma | not yet recruiting | Phase 2 | 32 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Sep 4, 2025 | clinicaltrials |
| NCT07141771 | An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing | not yet recruiting | Phase 1 / Phase 2 | 100 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT07110363 | A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer | not yet recruiting | Phase 1 | 58 | Biotroy TherapeuticsINDUSTRY | 0 | Aug 7, 2025 | clinicaltrials |
| NCT07106528 | Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer | not yet recruiting | Phase 2 / Phase 3 | 128 | Peking Union Medical College HospitalOTHER | 0 | Aug 6, 2025 | clinicaltrials |
| NCT07103408 | A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 56 | Sun Yat-sen UniversityOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT07097948 | Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033(Adjuvant) | not yet recruiting | Phase 2 | 40 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07076914 | Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy(PPI-PROTECT) | not yet recruiting | Phase 2 | 58 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07076095 | A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer | not yet recruiting | Phase 2 | 200 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 0 | Jul 21, 2025 | clinicaltrials |
| NCT07069270 | A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy | not yet recruiting | Phase 2 | 28 | Fujian Cancer HospitalOTHER_GOV | 0 | Jul 16, 2025 | clinicaltrials |
| NCT07063407 | Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer | not yet recruiting | Phase 1 | 50 | Shanghai Hansoh Biomedical Co., LtdINDUSTRY | 0 | Jul 14, 2025 | clinicaltrials |
| NCT05557708 | A Safety Study of 212Pb-Pentixather Radioligand Therapy | not yet recruiting | Early Phase 1 | 20 | Yusuf MendaOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT07048964 | A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations | not yet recruiting | — | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jul 3, 2025 | clinicaltrials |
| NCT07014540 | A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma | not yet recruiting | Phase 4 | 45 | Beijing GoBroad HospitalOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT07004712 | Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer | not yet recruiting | Phase 2 | 46 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06978153 | This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemotherapy With or Without Anlotinib in Resectable Limited-Stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 66 | Tang-Du HospitalOTHER | 0 | May 18, 2025 | clinicaltrials |
| NCT06961201 | Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase | not yet recruiting | Phase 3 | 94 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 7, 2025 | clinicaltrials |
| NCT06951841 | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction | not yet recruiting | Phase 4 | 31 | China Medical University, ChinaOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06914050 | Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Apr 25, 2025 | clinicaltrials |
| NCT06931145 | Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer | not yet recruiting | Phase 4 | 50 | Peking Union Medical College HospitalOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06909383 | Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm Phase II Clinical Study | not yet recruiting | Phase 2 | 41 | Guangzhou Institute of Respiratory DiseaseOTHER | 0 | Apr 3, 2025 | clinicaltrials |
| NCT06775002 | SERS-Based Serum Molecular Spectral Screening for Lung Cancer Type | not yet recruiting | — | 223 | Fuzhou General HospitalOTHER | 0 | Mar 31, 2025 | clinicaltrials |
| NCT06789796 | a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy. | not yet recruiting | Phase 3 | 636 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 11, 2025 | clinicaltrials |
| NCT06820762 | Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study | not yet recruiting | Phase 2 | 40 | The Second Affiliated Hospital of Dalian Medical UniversityOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06793228 | Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia | not yet recruiting | Phase 2 | 250 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06786312 | A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer | not yet recruiting | Phase 2 | 34 | Fujian Cancer HospitalOTHER_GOV | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06784206 | Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06739421 | The Diagnostic Value of Bronchoscopic Needle-based Confocal Laser Endomicroscopy (nCLE) As a Real-time Detection Tool for Diagnosing Peripheral Lung Cancer: a Multi-centre Randomised Controlled Trial | not yet recruiting | N/A | 1,040 | China-Japan Friendship HospitalOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06724263 | A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors | not yet recruiting | Phase 2 | 120 | Tasly Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06719336 | Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001) | not yet recruiting | Phase 3 | 182 | Anhui Shi, MDOTHER | 0 | Dec 5, 2024 | clinicaltrials |
| NCT06672133 | Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC(RALLY) | not yet recruiting | Phase 3 | 524 | Jinming YuOTHER | 0 | Nov 5, 2024 | clinicaltrials |
| NCT06597513 | Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC | not yet recruiting | Phase 1 / Phase 2 | 10 | Zhou ChengzhiOTHER | 0 | Oct 15, 2024 | clinicaltrials |
| NCT06620796 | A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 70 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Oct 1, 2024 | clinicaltrials |
| NCT06614621 | A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 43 | Fujian Cancer HospitalOTHER_GOV | 0 | Sep 26, 2024 | clinicaltrials |
| NCT06497543 | Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic | not yet recruiting | Phase 2 | 80 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06581380 | JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 394 | JenKem Technology Co., Ltd.INDUSTRY | 0 | Sep 3, 2024 | clinicaltrials |
| NCT06554535 | Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 43 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Aug 15, 2024 | clinicaltrials |
| NCT06526624 | A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 406 | Hansoh BioMedical R&D CompanyINDUSTRY | 0 | Jul 30, 2024 | clinicaltrials |
| NCT06462105 | Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer | not yet recruiting | N/A | 60 | Zhou ChengzhiOTHER | 0 | Jun 28, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 4, 2026source: clinicaltrials